Moreover, a drug called SU5271 that inhibits the activity of EGFR has been verified to suppress the proliferation of keratinocytes in an initial clinical trial 9, which demonstrates that EGFR can act as a therapy target for psoriasis. Here, EGFR is linked to psoriasis.